NervGen Pharma NGEN 深 滬
等待開盤 08-21 09:30:00 美东时间
1.76
+0.010
+0.57%
華盛通- 最 高1.77
- 今 開1.75
- 成交量 25.33万股
- 最 低 1.6845
- 昨 收 1.75
- 總市值 1.87亿
- 52周最高 6.30
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 1.58
- 委 比 -97.64%
- 總股本 1.06亿
- 歷史最高 6.30
- 量 比 0.51
- 振 幅 4.89%
- 歷史最低 1.58
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10
Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Outperform rating and announces Price Target of $10.
07-14 01:59
NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M
U.S.$250,000,000Common SharesDebt SecuritiesSubscription ReceiptsWarrantsUnitsThe amended and restated short form base shelf prospectus dated December 15, 2025 (the "Prospectus") of NervGen Pharma Corp. ("NervGen"
05-26 21:31
Why Is NervGen Pharma Stock Gaining Tuesday?
NGEN stock climbs as NervGen Pharma NVG-291 hits a 100% responder rate in spinal cord injury gait analysis. Phase 3 set for mid-2026.
05-26 20:33
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
NervGen Pharma Announces Commencement Of Public Offering Of Common Shares
The offering is being made pursuant to a prospectus supplement to an amended and restated short form base shelf prospectus dated December 15, 2025 (the "Base Shelf Prospectus") filed in all of the provinces and
05-22 04:06
NervGen Announces Proposed Public Offering of Securities
NervGen Pharma Corp. has launched an underwritten public offering of common shares and warrants to raise funds for advancing its lead therapeutic candidate, NVG-291, through clinical studies and general corporate purposes. The offering is being managed by Leerink Partners and TD Cowen. The Base Shelf Prospectus and the prospectus supplement will be accessible via SEDAR+ and EDGAR. The final terms will be disclosed in the final prospectus suppleme...
05-21 20:01
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported progress on its NVG-291 clinical development, including FDA alignment on the RESTORE study parameters for chronic tetraplegia, ongoing CONNECT SCI biomechanical gait analyses, and plans to initiate the RESTORE study in mid-2026. The company listed on Nasdaq under 'NGEN' and strengthened its leadership team with key senior appointments. Financially, NervGen ended Q1 2026 with $16.6M in cash and investments, increased ...
05-18 11:15
